LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
27 funds hold it · Insiders net selling
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Period ending
Oct 2, 2026
Earnings per share
$0.90 expected
Estimates as of Nov 9, 2026
EPS expected
$0.82 to $1.22
Revenue expected
14 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Oct 2, 2026Reported Oct 29, 2026 | $0.94est. $0.90 | +3.98%beat | $658.7MSEC filing | +10.2%from $597.8M |
| Jul 3, 2026Reported Aug 5, 2026 | $0.91est. $0.86 | +5.93%beat | $628.7MSEC filing | +10.6%from $568.3M |
| Apr 3, 2026Reported May 5, 2026 | $0.87est. $0.76 | +14.02%beat | $610.8MSEC filing | +10.0%from $555.4M |
| Dec 31, 2025Reported Feb 10, 2026 | $0.94est. $0.81 | +16.17%beat | $598.7MAlpha Vantage | +5.6%from $566.8M |
| Oct 3, 2025Reported Nov 4, 2025 | $0.78est. $0.67 | +16.42%beat | $597.8MSEC filing | +10.8%from $539.5M |
| Jul 4, 2025Reported Jul 28, 2025 | $0.75est. $0.65 | +15.38%beat | $568.3MSEC filing | -10.8%from $637.2M |
| Apr 4, 2025Reported May 13, 2025 | $0.62est. $0.37 | +69.12%beat | $555.4MSEC filing | +30.6%from $425.2M |
| Dec 31, 2024Reported Feb 11, 2025 | $0.55est. $0.49 | +12.24%beat | $566.8MAlpha Vantage | +18.2%from $479.7M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $598.7M | $610.8M | $628.7M | $658.7M |
| Cost of what it sold | $26.5M | $20.0M | $20.7M | $26.2M |
| Gross profit | $572.2M | $590.9M | $608.0M | $632.5M |
| What it spent | ||||
| Research and development | $213.2M | $199.9M | $212.0M | $209.5M |
| Sales and admin | $71.3M | $139.6M | $147.6M | $154.6M |
| Other operating costs | $52.4M | — | — | — |
| Total operating expenses | $337.0M | $339.5M | $359.6M | $364.0M |
| What was left | ||||
| Operating profit | $235.2M | $251.3M | $248.4M | $268.4M |
| Profit before tax | $252.7M | $267.7M | $262.7M | $282.8M |
| Tax | $8.2M | $57.2M | $50.6M | $64.7M |
| Net profit | $244.5M | $210.5M | $212.1M | $218.1M |
| EBITDA | $242.9M | $274.6M | $269.7M | $289.7M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib
Leans bullishNov 11Eight Farallon funds hold the shares behind a passive stake in Exelixis (EXEL).
NeutralNov 10A 12 million-share Exelixis (EXEL) stake falls below the 5% ownership threshold.
NeutralNov 10Exelixis stock: Q3 revenue rises as zanzalintinib advances
BullishNov 6Handa Pharmaceuticals' First Three Quarters Profit Falls Over 70%; Originator Files New Patent Infringement Suit, Shares Hit Limit Down
Leans bullishNov 6Exelixis Inc stock hits all-time high at 73.49 USD
BullishNov 5Exelixis Inc stock hits all-time high at 73.49 USD By Investing.com
BullishNov 5What Was Exelixis Telling You Before Its Stock Ran?
BullishNov 134 macro signals shaping EXEL right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
